Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study

Nursing and Health Professions

• Nilotinib 100%
• Imatinib 70%
• Chronic Myeloid Leukemia 50%
• Patient 40%
• Combination Therapy 20%
• Food and Drug Administration 10%
• Disease Marker 10%
• Philadelphia 1 Chromosome 10%
• Monitoring 10%
• Inpatient 10%
• Adult 10%
• Phosphotransferase 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Nilotinib 100%
• Imatinib 70%
• Chronic Myeloid Leukemia 50%
• Clinical Trial 30%
• Phosphotransferase 10%
• Philadelphia 1 Chromosome 10%
• Disease Marker 10%

INIS

• patients 50%
• myeloid leukemia 50%
• clinical trials 30%
• safety 30%
• monitoring 10%
• therapy 10%
• adults 10%
• failures 10%
• kinases 10%
• inhibition 10%
• power 10%
• philadelphia chromosome 10%
• us fda 10%